TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma.

June 21, 2017

prudect name : TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma.
TAK-901

Synonyms: CAS NO: 934541-31-8Molecular Formula: C₂₈H₃₂N₄O₃SMolecular Weight: 504.64Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com